key: cord-0824664-oh19bnmg authors: Schasfoort, Richard B.M.; van Weperen, Jos; van Amsterdam, Margot; Parisot, Judicaël; Hendriks, Jan; Koerselman, Michelle; Karperien, Marcel; Mentink, Anouk; Bennink, Martin; Krabbe, Hans; Terstappen, Leon WMM.; Mulder, A.H. Leontine title: Presence and strength of binding of IgM, IgG and IgA antibodies against SARS-CoV-2 during CoViD-19 infection date: 2021-03-16 journal: Biosens Bioelectron DOI: 10.1016/j.bios.2021.113165 sha: c7a9f8c974ef7d53884e0a141ecd2712b945b324 doc_id: 824664 cord_uid: oh19bnmg Surface Plasmon Resonance imaging (SPRi) was used to determine the presence and strength of binding of IgG, IgM and IgA against the Receptor Binding Domain (RBD) of SARS-CoV-2 in sera of 119 CoViD-19 patients. The SPRi assay measures the antibody isotype levels and the strength of binding to the RBD of ultimate 384 patient samples in one run. It turns out that during the course of the disease, the IgG levels and strength of binding increased while generally the IgM and IgA levels go down. Recovered patients all show high strength of binding of the IgG type to the RBD protein. The anti-RBD immunoglobulins SPRi assay provides additional insights in the immune status of patients recovering from CoViD-19 and this new method can furthermore be applied for the assessment of the quality of the immune reaction of healthy individuals to SARS-CoV-2 in vaccination programs. Corona viruses pose serious health threats to humans and animals. SARS-CoV-2 crossed the species barrier again and causes serious respiratory infections in humans. In contrast to SARS-CoV that appeared in 2003 and the Middle East respiratory syndrome (MERS) in 2012, SARS-CoV-2 shows an unprecedented pandemic spread. Diagnostic tests of individuals, who are suspected of SARS-CoV-2 infection, mainly rely on real-time reverse transcription polymerase chain reaction (rRT-PCR) of viral genetic material collected in nasopharyngeal swabs [Chen C. et al. 2020 , Vashist K.S. 2020 . In contrast to the PCR test, serologic assays demonstrate the presence of an immune reaction against the virus through detection of immunoglobulins directed against SARS-CoV-2 structural proteins ]. The immune system of a CoViD-19 patient produces antibodies to SARS-CoV-2 within days to a few weeks following viral infection [Long et al., 2020, ] . Antibodies will remain for months following infection, as previously shown following the 2003 outbreak of SARS-CoV-1 [Cao et al., 2007] although the levels decline for SARS-CoV-2 [Beaudoin-Bussières G et al., 2020] . The immune reaction to corona viruses generally provides immunity via neutralizing antibodies [Yuchun et al., 2004] in the event of a second exposure to the virus and this also provides the basis for vaccine development. Serological antibody testing [Jin et al., 2020] is essential to get an indication whether or not an individual has been infected with SARS-CoV-2 in the past. The quality of the immune response is not only determined by the amount of antibodies but also by the overall strength of binding of the pool of potential neutralizing antibodies that binds to the relevant immunogenic proteins of the Corona virus. Recently, it was shown that the most potent, highest affinity neutralizing antibodies were directed to the receptor-binding domain (RBD) [Brouwer et al., 2020] . This spike protein RBD of SARS-CoV-2 domain binds to the angiotensin converting enzyme2 (ACE2) receptor expressed by many cell types from epithelial cells, to blood vessels, kidneys and gastrointestinal tract, and abundant on pneumocytes-hence the respiratory symptoms. The high ACE2 binding affinity of the RBD, furin preactivation of the spike, and hidden RBD in the spike potentially allow SARS-CoV-2 to maintain efficient cell entry while evading immune surveillance [Shang et al. 2020] . The affinity of the RBD of SARS-CoV and SARS-CoV-2 to the ACE2 receptor appeared to be approximately 31 nM and K D ~ (